A small pediatric study found that adoptive NK cell infusions eliminated HHV-6B encephalitis, while maintaining a low rate of GVHD. At a ratio of NK/CD4 >2, the HHV-6B reactivation rate dropped dramatically.
HHV-6 was the most prevalent virus in febrile neutropenia episodes among pediatric patients
HHV-6B infection of primary monocytes induces cell-associated and soluble PD-L1 production, increased intracellular ROS and activation of STAT1 and STAT3 pathways
A small study found a strong association between HHV-6 infection of the placenta and intrauterine growth restriction—a finding consistent with other evidence linking HHV-6 to several reproductive diseases.
CD45, important in T cell receptor signaling, may be one mechanism by which roseolaviruses evade immune detection and help achieve latency
A Japanese group found that ciHHV6 genes encoding for immunoglobulins were decreased in ciHHV6 individuals, possibly modulating immune responses.
Cytokine and chemokine responses were very similar in HHV-6B and HHV-7 infections. The results were starkly different for HHV-6A.
University of Washington investigators utilized rare cell enrichment and an HLA-agnostic, proteome-wide approach to expand the library of known HHV-6 T cell antigens from 11 to 60.
University of Massachusetts investigators have identified 25 new naturally processed peptide sequences using mass spectrometry.
A French group studied immunological responses to HHV-6 and CMV in healthy adults ex vivo and found that HHV-6 induces an excessive number of potently immunosuppressive T regulatory cells that block dendritic cell maturation and functions.
A prospective study of allogenic stem cell transplant patients in Japan suggests that the percentage of CD134+ T cells could be used to predict which patients are vulnerable to HHV-6 reactivation. The authors propose that further investigation into the effect of elevated CD134+ T cells pre-transplant is warranted.
Yasuko Mori and colleagues were successful in humanizing two neutralizing monoclonal antibodies to HHV-6B. The chimeric antibodies performed well enough to show promise for therapeutic use.
“Off-the-shelf” donor T cells primed to fight five specific viruses were shown to be effective in a Phase 2 trial backed by Viracyte. A single infusion produced a complete or partial response rate of 92%.